Synthetic peptides containing ITIM-like domains block expression of inflammatory mediators and migration/invasion of cancer cells through activation of SHP-1 and PI3K

Cancer Investigation

Volumn 30, Issue 5, 2012, Pages 364-371

  Kim, Jae Kwan ^a   Lee, Sang Min ^a   Suk, Kyoungho ^b   Lee, Won Ha ^a  

^a Kyungpook National University   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

Author keywords

Cancer; Inflammation; Invasion; IREM 1; ITIM; Migration

Indexed keywords

IMMUNORECEPTOR TYROSINE BASED INHIBITORY MOTIF; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE PHOSPHATASE SHP 1; RECEPTOR; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE MARROW CELL; CANCER CELL; CANCER CELL CULTURE; CANCER INVASION; CELL MIGRATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; INHIBITION KINETICS; MEDIATOR; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CELL LINE, TUMOR; CELL MOVEMENT; DNA; HUMANS; INFLAMMATION MEDIATORS; NEOPLASM INVASIVENESS; NF-KAPPA B; PEPTIDES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN STRUCTURE, TERTIARY; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84861058998     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2012.664671     Document Type: Article

References (42)

1. Alvarez-Errico D, Aguilar H, Kitzig F, Brckalo T, Sayos J, Lopez- Botet M. IREM-1 is a novel inhibitory receptor expressed by myeloid cells. Eur J Immunol 2004;34(12):3690-3701. (Pubitemid 40012187)
2. Chung DH, Humphrey MB, Nakamura MC, Ginzinger DG, Seaman WE, Daws MR. CMRF-35-like molecule-1, a novel mouse myeloid receptor, can inhibit osteoclast formation. J Immunol 2003;171(12):6541-6548. (Pubitemid 37532084)
3. Shibuya A, Nakahashi-Oda C, Tahara-Hanaoka S. Regulation of immune responses by the activating and inhibitory myeloidassociate immunoglobuline-like receptors (MAIR) (CD300). Immune Netw 2009;9(2):41-45.
4. Sui L, Li N, Liu Q, Zhang W, Wan T, Wang B, Luo K, Sun H, Cao X. IgSF13, a novel human inhibitory receptor of the immunoglobulin superfamily, is preferentially expressed in dendritic cells and monocytes. Biochem Biophys Res Commun 2004;319(3):920-928. (Pubitemid 38739408)
5. Izawa K, Kitaura J, Yamanishi Y,Matsuoka T, Kaitani A, Sugiuchi M, Takahashi M, Maehara A, Enomoto Y, Oki T, Takai T, Kitamura T. An activating and inhibitory signal from an inhibitory receptor LMIR3/CLM-1: LMIR3 augments lipopolysaccharide response through association with FcRgamma in mast cells. J Immunol 2009;183(2):925-936.
6. Lee SM, Nam YP, Suk K, Lee WH. IREM-1 inhibits BAFFmediated inflammatory regulation of THP-1 cells through modulation of the activities of ERK. Clin Exp Immunol 2010;161(3):504-511.
7. Xi H., Katschke KJ, , Helmy KY, Wark PA, Kljavin N, Clark H, Eastham-Anderson J, Shek T, Roose-Girma M, Ghilardi N, van Lookeren Campagne M. Negative regulation of autoimmune demyelination by the inhibitory receptor CLM-1. J Exp Med 2010;207(1):7-16, S11-15.
8. Alvarez-Errico D, Sayos J, Lopez-Botet M. The IREM-1 (CD300f) inhibitory receptor associates with the p85alpha subunit of phosphoinositide 3-kinase. J Immunol 2007;178(2):808-816. (Pubitemid 46095153)
9. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454(7203):436-444.
10. Philip M, Rowley DA, Schreiber H. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol 2004;14(6):433-439. (Pubitemid 39360991)
11. Mantovani A, Schioppa T, Porta C, Allavena P, Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metast Rev 2006;25(3):315-322. (Pubitemid 44922352)
12. Sica A, Allavena P, Mantovani A. Cancer related inflammation: the macrophage connection. Cancer Lett 2008;267(2):204-215.
13. Clevers H. At the crossroads of inflammation and cancer. Cell 2004;118(6):671-674. (Pubitemid 39221727)
14. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res 2006;4(4):221-233.
15. Lee SM, Kim EJ, Suk K, Lee WH. CD300F blocks both MyD88 and TRIF-mediated TLR signaling through activation of SHP-1. J Immunol 2011;186(11):6296-6303.
16. Lee SM, Kim EJ, Suk K, Lee WH. Stimulation of FasL induces production of pro-inflammatory mediators through activation of mitogen activated protein kinases and nuclear factor-kappaB in THP-1 cells. Inflammation 2012;35(1):1-10.
17. Vives E, Richard JP, Rispal C, Lebleu B. TAT peptide internalization: seeking the mechanism of entry. Curr Protein Pept Sci 2003;4(2):125-132. (Pubitemid 36834011)
18. Kim WJ, Lee WH. LIGHT is expressed in foam cells and involved in destabilization of atherosclerotic plaques through induction of matrix metalloproteinase-9 and IL-8. Immune Netw 2004;4(2):116-122.
19. Lee WH, Kim SH, Lee Y, Lee BB, Kwon B, Song H, Kwon BS, Park JE. Tumor necrosis factor receptor superfamily 14 is involved in atherogenesis by inducing proinflammatory cytokines and matrix metalloproteinases. Arterioscler Thromb Vasc Biol 2001;21(12):2004-2010. (Pubitemid 34219754)
20. Lee SH, Kim EJ, Suk K, Kim IS, LeeWH. TL1A induces the expression of TGF-beta-inducible gene h3 (betaig-h3) through PKC, PI3K, and ERK in THP-1 cells. Cell Immunol 2010;266(1):61-66.
21. Rosenau C, Emery D, Kaboord B, Qoronfleh MW. Development of a high-throughput plate-based chemiluminescent transcription factor assay. J Biomol Screen 2004;9(4):334-342.
22. Arabaci G, Guo XC, Beebe KD, Coggeshall KM, Pei D. α- Haloacetophenone derivatives as photoreversible covalent inhibitors of protein tyrosine phosphatases. J Am Chem Soc 1999;121:5085-5086. (Pubitemid 29269148)
23. Lorenz U. SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels. Immunol Rev 2009;228(1):342-359.
24. Fayard E, Xue G, Parcellier A, Bozulic L, Hemmings BA. Protein kinase B (PKB/Akt): a key mediator of the PI3K signaling pathway. Curr Top Microbiol Immunol 2010;346:31-56.
25. Carpenter CL, Auger KR, Chanudhuri M, Yoakim M, Schaffhausen B, Shoelson S, Cantley LC. Phosphoinositide 3-kinase is activated by phosphopeptides that bind to the SH2 domains of the 85-kDa subunit. J Biol Chem 1993; 268(13):9478-9483. (Pubitemid 23146000)
26. Street A, Macdonald A, Crowder K, Harris M. The hepatitis C virus NS5A protein activates a phosphoinositide 3- kinase-dependent survival signaling cascade. J Biol Chem 2004;279(13):12232-12241. (Pubitemid 38445788)
27. Lee SM, Kim EJ, Suk K, LeeWH. Synthetic peptides containing ITIM-like sequences of IREM-1 inhibit BAFF-mediated regulation of interleukin-8 expression and phagocytosis through SHP-1 and/or PI3K. Immunology 2011;134(2):224-233.
28. Chong ZZ, Maiese K. The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury. Histol Histopathol 2007; 22(11):1251-1267. (Pubitemid 47470319)
29. Christophi GP, Hudson CA, Panos M, Gruber RC, Massa PT. Modulation of macrophage infiltration and inflammatory activity by the phosphatase SHP-1 in virus-induced demyelinating disease. J Virol 2009;83(2):522-539.
30. Christophi GP, Massa PT. Central neuroinvasion and demyelination by inflammatorymacrophages after peripheral virus infection is controlled by SHP-1. Viral Immunol 2009;22(6):371-387.
31. Christophi GP, Panos M, Hudson CA, Christophi RL, Gruber RC, Mersich AT, Blystone SD, Jubelt B, Massa PT. Macrophages of multiple sclerosis patients display deficient SHP- 1 expression and enhanced inflammatory phenotype. Lab Invest 2009;89(7):742-759.
32. Hardin AO, Meals EA, Yi T, Knapp KM, English BK. SHP-1 inhibits LPS-mediated TNF and iNOS production in murine macrophages. Biochem Bioph Res Commun 2006;342(2):547-555. (Pubitemid 43289025)
33. Guha M, Mackman N. The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J Biol Chem 2002;277(35):32124-32132. (Pubitemid 34969025)
34. Strassheim D, Asehnoune K, Park JS, Kim JY, He Q, Richter D, Kuhn K,Mitra S, Abraham E. Phosphoinositide 3-kinase and Akt occupy central roles in inflammatory responses of Toll-like receptor 2-stimulated neutrophils. J Immunol 2004;172(9):5727-5733. (Pubitemid 38542078)
35. Diaz-Guerra MJ, Castrillo A, Martin-Sanz P, Bosca L. Negative regulation by phosphatidylinositol 3-kinase of inducible nitric oxide synthase expression in macrophages. J Immunol 1999;162(10):6184-6190. (Pubitemid 29314981)
36. Li X, Tupper JC, Bannerman DD, Winn RK, Rhodes CJ, Harlan JM. Phosphoinositide 3 kinase mediates Toll-like receptor 4- induced activation of NF-kappa B in endothelial cells. Infect Immun 2003;71(8):4414-4420. (Pubitemid 36919907)
37. Pahan K, Raymond JR, Singh I. Inhibition of phosphatidylinositol 3-kinase induces nitric-oxide synthase in lipopolysaccharide- or cytokine-stimulated C6 glial cells. J Biol Chem 1999;274(11):7528-7536.
38. Aksoy E, Vanden Berghe W, Detienne S, Amraoui Z, Fitzgerald KA, Haegeman G, Goldman M, Willems F. Inhibition of phosphoinositide 3-kinase enhances TRIF-dependent NF-kappa B activation and IFN-beta synthesis downstream of Toll-like receptor 3 and 4. Eur J Immunol 2005;35(7):2200-2209. (Pubitemid 41015059)
39. Bansal K, Kapoor N, Narayana Y, Puzo G, Gilleron M, Balaji KN. PIM2 induced COX-2 and MMP-9 expression in macrophages requires PI3K and Notch1 signaling. PloS One 2009;4(3): e4911.
40. BarberMA,WelchHC. PI3KandRAC signalling in leukocyte and cancer cell migration. Bull Cancer 2006;93(5):E44-E52.
41. Dagia NM, Agarwal G, Kamath DV, Chetrapal-Kunwar A, Gupte RD, Jadhav MG, Dadarkar SS, Trivedi J, Kulkarni-Almeida AA, Kharas F, et al. A preferential p110alpha/gamma PI3K inhibitor attenuates experimental inflammation by suppressing the production of proinflammatory mediators in a NF-kappaB-dependent manner. Am J Physiol 2010;298(4):C929-941.
42. Lee IT, Lee CW, Tung WH,Wang SW, Lin CC, Shu JC, Yang CM. Cooperation of TLR2 withMyD88, PI3K, and Rac1 in lipoteichoic acid-induced cPLA2/COX-2- dependent airway inflammatory responses. Am J Pathol 2010;176(4):1671-1684.